US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CAR-T Concept

1,384.89

-3.8358-0.28%

Number of Gainers:1

Number of Losers:1

Number of Flat:- -

PE:- -

High:1,388.65

Open:1,386.78

Low:1,373.00

Close:1,388.72

Loading ...

Daniel Patrick O'Day, Chairman & CEO, Reports Disposal of Common Shares in Gilead Sciences Inc

Zacks.com featured highlights Novartis, ENGIE, MasTec, Dorman Products and Sterling Infrastructure

bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital

THOMSON REUTERS

Press Release: bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital

Gilead Sciences (GILD) Gets a Hold from Truist Financial

Novartis Reports New Data From Phase 2 Trial of Kisqali in Breast Cancer

MT Newswires Live

Novartis Says Pluvicto Shows Benefit in Early Prostate Cancer Study

MT Newswires Live

Novartis announces data from new subgroup analysis of Phase III NATALEE trial

Gilead’s Kite announces real-world safety, effectiveness of Yescarta

Gilead Sciences Reveals Promising Results of Yescarta® in Outpatient Care for Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025

Gilead's CAR-T cell therapy shows promise in deadly brain cancer

Gilead Sciences Unveils Promising Phase 3 Results: Trodelvy Plus Keytruda Reduces Disease Progression Risk by 35% in Metastatic Triple-Negative Breast Cancer

Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer

THOMSON REUTERS

Press Release: Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer

Backpack has launched spot trading for WAL, DEEP, SEND, BLUE, HAEDAL, and NS.

Sui Ecosystem Token Resurgence, SUI Up 7.2% in 24 Hours

Gene Therapy Death Worsens Picture for an Already Troubled Field -- Barrons.com

Bluebird Bio Urges Stockholders to Tender Shares as Carlyle and SK Capital Acquisition Deadline Approaches

Sui Ecosystem Token Surges, SEND Sees 22% 24-hour Price Increase

Gilead Sciences Inc. Chief Commercial Officer Johanna Mercier Reports Disposal of Common Shares

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4578/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4578","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","market":"US","secType":"PLATE","nameCN":"CAR-T Concept","latestPrice":1384.8889,"timestamp":1748980799999,"preClose":1388.7247,"halted":0,"volume":11617117,"delay":0,"changeRate":-0.002762,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-3.835815,"latestTime":"06-03 16:00:00 EDT","open":1386.7797,"high":1388.6475,"low":1373.0044,"amount":1279440050.000165,"amplitude":0.011264,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1749043800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":6.295946,"peRate":19.242036,"turnoverRate":0.003813,"increases":1,"decrements":1,"flats":0,"marketCap":363154669568,"floatMarketCap":345052241920},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","high":1388.6475,"amplitude":0.011264,"preClose":1388.7247,"low":1373.0044,"pbRate":"6.295946","latestPrice":1384.8889,"volume":11617117,"delay":0,"open":1386.7797,"prevYearClose":1164.883,"prevWeekClose":1387.2515,"prevMonthClose":1387.2515,"prevQuarterClose":1364.0579,"fiveDayClose":1363.2053,"twentyDayClose":1332.5844,"sixtyDayClose":1419.5145,"secType":"PLATE","market":"US","turnoverRate":0.003813,"peRate":19.242036,"marketCap":363154669568,"floatMarketCap":345052241920,"timestamp":1748980799999,"nameCN":"CAR-T Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4578\",,,,undefined,":{"bkCode":"BK4578","up":1,"down":1,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4578\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2540871443","title":"Daniel Patrick O'Day, Chairman & CEO, Reports Disposal of Common Shares in Gilead Sciences Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2540871443","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540871443?lang=en_us&edition=fundamental","pubTime":"2025-06-03 08:56","pubTimestamp":1748912188,"startTime":"0","endTime":"0","summary":"Daniel Patrick O'Day, Chairman and CEO of Gilead Sciences Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 02, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL1PrYrW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Daniel Patrick O'Day, Chairman & CEO, Reports Disposal of Common Shares in Gilead Sciences Inc","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1839511570.USD","BK4550","IE0002270589.USD","LU1778281490.HKD","LU1674673691.USD","LU1674673428.USD","IE00B7SZLL34.SGD","LU0823416689.USD","BK4568","IE00BSNM7G36.USD","LU0109394709.USD","LU0320765992.SGD","LU1066051498.USD","LU2089984988.USD","BK4585","BK4532","BK4139","LU2087621335.USD","LU1066053197.SGD","BK4588","IE00B3T34201.USD","LU0058720904.USD","LU0234570918.USD","BK4566","LU1585245621.USD","LU1430594728.SGD","BK4578","BK4583","IE00B19Z3B42.SGD","LU0889565916.HKD","LU0289739699.SGD","GILD","LU1571399168.USD","IE00B19Z3581.USD","LU2468319806.SGD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2540334950","title":"Zacks.com featured highlights Novartis, ENGIE, MasTec, Dorman Products and Sterling Infrastructure","url":"https://stock-news.laohu8.com/highlight/detail?id=2540334950","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540334950?lang=en_us&edition=fundamental","pubTime":"2025-06-02 20:44","pubTimestamp":1748868240,"startTime":"0","endTime":"0","summary":"Chicago, IL – June 2, 2025 – The stocks in this week’s article are Novartis NVS, ENGIE SA ENGIY, MasTec MTZ, Dorman Products DORM and Sterling Infrastructure, Inc. STRL.Buy These 5 Low-Leverage Stocks Amid Volatile Market Sentiment. The U.S. stock market showed mixed signals on May 29, with investors reacting to a combination of events. While NVIDIA’s strong quarterly results and a favorable ruling from the U.S. International Trade court against Trump-imposed tariffs supported gains on the Nasdaq and S&P 500, the Dow Jones slipped, weighed down by investor concerns over the broader economic outlook amid escalating geopolitical uncertainties.Given such volatile market sentiment, prudent investors are expected to choose safe bet stocks like Novartis, ENGIE SA, MasTec, Dorman Products and Sterling Infrastructure, Inc. to safeguard their portfolio from huge losses . These stocks bear low leverage and, therefore, should be a safer option for investors if they don’t want to lose big in times","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zacks-com-featured-highlights-novartis-124400569.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0320765489.SGD","BK4208","IE00B2B36J28.USD","DORM","BK4129","BK4532","BK4578","LU0211331839.USD","BK4588","LU1559883803.SGD","IE0002141913.USD","MTZ","ENGIY","IE0009355771.USD","IE00BJJMRZ35.SGD","LU2065731478.USD","BK4124","LU0566484027.USD","LU2463526074.USD","LU0070302665.USD","NVS","LU1093756325.SGD","IE00B4R5TH58.HKD","ENGQF","BK4585","LU2355687059.USD","IE00BFTCPJ56.SGD","LU0208291251.USD","BK4007","IE00BJT1NW94.SGD","LU1093756168.USD","STRL"],"gpt_icon":0},{"id":"2540798498","title":"bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2540798498","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540798498?lang=en_us&edition=fundamental","pubTime":"2025-06-02 20:34","pubTimestamp":1748867640,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nTUAC46HXX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4556","BK4578","BLUE"],"gpt_icon":0},{"id":"2540244798","title":"Press Release: bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2540244798","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540244798?lang=en_us&edition=fundamental","pubTime":"2025-06-02 20:34","pubTimestamp":1748867640,"startTime":"0","endTime":"0","summary":"New management, led by David Meek, is committed to rapidly scaling access to lifechanging gene therapies. Significant capital commitment from Carlyle and SK Capital will enable bluebird to grow and accelerate patient access. bluebird will focus on expanding manufacturing capacity and improving the treatment experience for patients and providers. David Meek, who became Chief Executive Officer of bluebird at close, said, \"Today marks the beginning of a new era for bluebird as its go-forward financial backing and leadership team will better enable all stakeholders to realize the full potential of our revolutionary therapies. Historically, bluebird has excelled as a scientific innovator and should be very proud of the many achievements it has delivered to patients. Our vision is to further that legacy of scientific excellence while improving the commercial execution of our approved products to rapidly expand access to lifechanging gene therapies.\". The company's momentum is reinforced by a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","BLUE","BK4139","IE00B64PRP62.GBP","BK4578","IE00BGHQF748.EUR","CG","IE00B3QW5Z07.USD","BK4135"],"gpt_icon":0},{"id":"2540976719","title":"Gilead Sciences (GILD) Gets a Hold from Truist Financial","url":"https://stock-news.laohu8.com/highlight/detail?id=2540976719","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540976719?lang=en_us&edition=fundamental","pubTime":"2025-06-02 19:17","pubTimestamp":1748863029,"startTime":"0","endTime":"0","summary":"Truist Financial analyst Asthika Goonewardene maintained a Hold rating on Gilead Sciences (GILD – Research Report) today. The company’s shares clos...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/gilead-sciences-gild-gets-a-hold-from-truist-financial-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/gilead-sciences-gild-gets-a-hold-from-truist-financial-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GILD","IE0002270589.USD","LU0234570918.USD","IE00B19Z3581.USD","BK4566","BK4550","LU0823416689.USD","LU0058720904.USD","LU1778281490.HKD","LU1571399168.USD","LU2087621335.USD","LU1066051498.USD","LU1430594728.SGD","LU0289739699.SGD","LU1674673428.USD","IE00BKVL7J92.USD","LU0889565916.HKD","LU1674673691.USD","BK4585","BK4568","BK4583","LU0320765992.SGD","LU2468319806.SGD","BK4532","IE00BSNM7G36.USD","IE00B3T34201.USD","LU0109394709.USD","BK4139","IE00B7SZLL34.SGD","LU1839511570.USD","LU2089984988.USD","IE00B19Z3B42.SGD","LU1066053197.SGD","IE00BZ1G4Q59.USD","BK4588","BK4578","LU1585245621.USD"],"gpt_icon":0},{"id":"2540641764","title":"Novartis Reports New Data From Phase 2 Trial of Kisqali in Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2540641764","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540641764?lang=en_us&edition=fundamental","pubTime":"2025-06-02 18:10","pubTimestamp":1748859006,"startTime":"0","endTime":"0","summary":"Novartis (NVS) said Sunday that data from a new subgroup analysis of a phase 2 trial evaluating Kisqali, plus endocrine therapy, in patients with stage II and III hormone receptor-positive/human epide","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BFTCPJ56.SGD","LU0320765489.SGD","LU0208291251.USD","IE00B2B36J28.USD","BK4585","LU0211331839.USD","BK4578","BK4532","BK4007","NVS","BK4588","IE00B4R5TH58.HKD","IE0002141913.USD","LU0070302665.USD","IE00BJJMRZ35.SGD","IE0009355771.USD","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2540764839","title":"Novartis Says Pluvicto Shows Benefit in Early Prostate Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2540764839","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540764839?lang=en_us&edition=fundamental","pubTime":"2025-06-02 17:59","pubTimestamp":1748858364,"startTime":"0","endTime":"0","summary":"Novartis  said Monday that its radioligand therapy, Pluvicto, combined with standard care, significantly improved radiographic progression-free survival in a pre-specified interim analysis of a phase 3 trial for patients with a certain type of prostate cancer.The drugmaker said a positive trend in overall survival was also observed.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BJT1NW94.SGD","LU0211331839.USD","BK4585","BK4532","IE00BJJMRZ35.SGD","NVS","BK4588","BK4578","IE00B4R5TH58.HKD","BK4007","LU0320765489.SGD","LU0070302665.USD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","IE0009355771.USD","IE0002141913.USD","LU0208291251.USD"],"gpt_icon":0},{"id":"2540753325","title":"Novartis announces data from new subgroup analysis of Phase III NATALEE trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2540753325","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540753325?lang=en_us&edition=fundamental","pubTime":"2025-06-02 07:30","pubTimestamp":1748820610,"startTime":"0","endTime":"0","summary":"Novartis (NVS) is announcing data from a new subgroup analysis of the Phase III NATALEE trial evaluating the efficacy and safety of Kisqali plus en...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-announces-data-from-new-subgroup-analysis-of-phase-iii-natalee-trial-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-announces-data-from-new-subgroup-analysis-of-phase-iii-natalee-trial-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0070302665.USD","BK4532","BK4007","LU0211331839.USD","IE00B4R5TH58.HKD","IE0002141913.USD","BK4578","IE0009355771.USD","IE00B2B36J28.USD","BK4585","LU0320765489.SGD","BK4588","IE00BJJMRZ35.SGD","LU0208291251.USD","BK4134","NVS","III","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD"],"gpt_icon":0},{"id":"2540953730","title":"Gilead’s Kite announces real-world safety, effectiveness of Yescarta","url":"https://stock-news.laohu8.com/highlight/detail?id=2540953730","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540953730?lang=en_us&edition=fundamental","pubTime":"2025-06-02 04:10","pubTimestamp":1748808616,"startTime":"0","endTime":"0","summary":"Kite, a Gilead (GILD) Company, announced real-world data evaluating the safety and effectiveness of Yescarta for patients with relapsed/refractory ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gileads-kite-announces-real-world-safety-effectiveness-of-yescarta-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gileads-kite-announces-real-world-safety-effectiveness-of-yescarta-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2468319806.SGD","LU1066051498.USD","IE00B19Z3B42.SGD","BK4578","LU1571399168.USD","LU1839511570.USD","LU1674673691.USD","LU1778281490.HKD","IE00BZ1G4Q59.USD","BK4568","GILD","LU2087621335.USD","BK4532","LU1585245621.USD","IE00B19Z3581.USD","LU0823416689.USD","LU0889565916.HKD","IE00BKVL7J92.USD","IE00B7SZLL34.SGD","LU1430594728.SGD","BK4231","LU0320765992.SGD","LU1066053197.SGD","LU0058720904.USD","LU2089984988.USD","BK4583","LU0234570918.USD","BK4585","LU1674673428.USD","BK4139","BK4550","BK4080","BK4566","IE0002270589.USD","LU0109394709.USD","IE00B3T34201.USD","LU0289739699.SGD","KRG","BK4588","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2540312587","title":"Gilead Sciences Reveals Promising Results of Yescarta® in Outpatient Care for Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2540312587","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540312587?lang=en_us&edition=fundamental","pubTime":"2025-06-01 20:00","pubTimestamp":1748779234,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via Business Wire  on June 01, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250601:nNDL1bkVxY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","LU0234570918.USD","LU1674673691.USD","BK4583","IE00B3T34201.USD","LU1585245621.USD","BK4550","IE00B7SZLL34.SGD","LU0109394709.USD","BK4566","LU2089984988.USD","LU1571399168.USD","LU0289739699.SGD","GILD","LU1778281490.HKD","LU1674673428.USD","LU1839511570.USD","LU0823416689.USD","BK4585","LU0320765992.SGD","BK4578","LU1066053197.SGD","BK4139","IE0002270589.USD","IE00B19Z3B42.SGD","IE00BZ1G4Q59.USD","LU1066051498.USD","BK4532","LU2468319806.SGD","LU2087621335.USD","IE00BKVL7J92.USD","LU0058720904.USD","LU1430594728.SGD","IE00B19Z3581.USD","LU0889565916.HKD","IE00BSNM7G36.USD","BK4588"],"gpt_icon":0},{"id":"2540731283","title":"Gilead's CAR-T cell therapy shows promise in deadly brain cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2540731283","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540731283?lang=en_us&edition=fundamental","pubTime":"2025-06-01 20:00","pubTimestamp":1748779200,"startTime":"0","endTime":"0","summary":"Gilead's CAR-T cell therapy shows promise in deadly brain cancerTherapy shrank tumors in 62% of patients in small trialResult was not lasting beyond a few months for most patients\"We're on the right t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250601:nL2N3S304Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","LU1674673691.USD","LU1839511570.USD","LU1585245621.USD","LU1430594728.SGD","LU2468319806.SGD","GILD","BK4578","BK4588","IE00BKVL7J92.USD","BK4566","LU1571399168.USD","LU1066051498.USD","IE00B19Z3B42.SGD","BK4568","BK4585","IE00B7SZLL34.SGD","BK4532","LU1674673428.USD","BK4550","IE00BZ1G4Q59.USD","BK4139","LU0109394709.USD","LU1066053197.SGD","BK4583","LU0058720904.USD","LU0320765992.SGD","LU2087621335.USD","IE00B3T34201.USD","LU0823416689.USD","LU0289739699.SGD","IE00BSNM7G36.USD","LU0234570918.USD","LU0889565916.HKD","IE0002270589.USD","LU2089984988.USD","LU1778281490.HKD"],"gpt_icon":0},{"id":"2539786187","title":"Gilead Sciences Unveils Promising Phase 3 Results: Trodelvy Plus Keytruda Reduces Disease Progression Risk by 35% in Metastatic Triple-Negative Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2539786187","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539786187?lang=en_us&edition=fundamental","pubTime":"2025-05-31 20:01","pubTimestamp":1748692863,"startTime":"0","endTime":"0","summary":"Gilead Sciences Unveils Promising Phase 3 Results: Trodelvy Plus Keytruda Reduces Disease Progression Risk by 35% in Metastatic Triple-Negative Breast Cancer. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via Business Wire  on May 31, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250531:nNDL5DpLrT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","LU2087621335.USD","LU1778281490.HKD","BK4550","IE00B7SZLL34.SGD","LU1430594728.SGD","BK4578","LU1674673691.USD","LU1585245621.USD","LU0109394709.USD","LU1839511570.USD","IE00BZ1G4Q59.USD","GILD","BK4588","BK4532","LU0289739699.SGD","IE00BKVL7J92.USD","LU0320765992.SGD","BK4585","IE00B3T34201.USD","LU0823416689.USD","BK4139","LU0234570918.USD","LU2089984988.USD","IE00BSNM7G36.USD","BK4566","LU1674673428.USD","IE00B19Z3B42.SGD","LU1571399168.USD","IE0002270589.USD","IE00B19Z3581.USD","LU1066053197.SGD","LU0889565916.HKD","LU2468319806.SGD","BK4583","LU1066051498.USD","BK4568"],"gpt_icon":0},{"id":"2539226932","title":"Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2539226932","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539226932?lang=en_us&edition=fundamental","pubTime":"2025-05-30 20:30","pubTimestamp":1748608200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nTUA59W9VJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B64PRP62.GBP","BK4139","IE00BGHQF748.EUR","CG","BK4135","BK4578","BK4556","IE00B3QW5Z07.USD","BLUE"],"gpt_icon":0},{"id":"2539222635","title":"Press Release: Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2539222635","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539222635?lang=en_us&edition=fundamental","pubTime":"2025-05-30 20:30","pubTimestamp":1748608200,"startTime":"0","endTime":"0","summary":"All conditions of the Offer have been satisfied and the parties expect to consummate the acquisition on June 2, 2025. Founded in 2010, bluebird has been setting the standard for gene therapy for more than a decade--first as a scientific pioneer and now as a commercial leader. bluebird has an unrivaled track record in bringing the promise of gene therapy out of clinical studies and into the real-world setting, having secured FDA approvals for three therapies in under two years. Today, we are proving and scaling the commercial model for gene therapy and delivering innovative solutions for access to patients, providers, and payers.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","CG","IE00B64PRP62.GBP","BLUE","BK4556","BK4578","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","BK4139"],"gpt_icon":0},{"id":"2539125281","title":"Backpack has launched spot trading for WAL, DEEP, SEND, BLUE, HAEDAL, and NS.","url":"https://stock-news.laohu8.com/highlight/detail?id=2539125281","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539125281?lang=en_us&edition=fundamental","pubTime":"2025-05-29 19:05","pubTimestamp":1748516700,"startTime":"0","endTime":"0","summary":"BlockBeats News, May 29, according to the official announcement, Backpack has launched WAL, DEEP, SEND, BLUE, HAEDAL, NS spot trading.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/296051","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["DEEP","WAL","BK4589","BK4578","BK4556","BK4588","LU1668664300.SGD","LU1791807156.HKD","BK4585","LU0106831901.USD","BK4139","BK4211","BLUE"],"gpt_icon":0},{"id":"2538448696","title":"Sui Ecosystem Token Resurgence, SUI Up 7.2% in 24 Hours","url":"https://stock-news.laohu8.com/highlight/detail?id=2538448696","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538448696?lang=en_us&edition=fundamental","pubTime":"2025-05-28 12:05","pubTimestamp":1748405100,"startTime":"0","endTime":"0","summary":"BlockBeats News, May 28, according to HTX market data, the Sui ecosystem tokens saw a rebound, including:SUI's market cap is now at $12.38 billion, with a 24-hour increase of 7.2%;WAL's market cap is now at $760 million, with a 24-hour increase of 8.02%;DEEP's market cap is now at $463 million, with a 24-hour increase of 7.98%;CETUS's market cap is now at $160 million, with a 24-hour increase of 33.2%;BLUE's market cap is now at $39.9 million, with a 24-hour increase of 1.98%;NAVX's market cap is now at $34 million, with a 24-hour increase of 2.75%.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/295800","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["BK4215","BK4211","SUI","LU0106831901.USD","BK4585","BK4589","LU1791807156.HKD","WAL","DEEP","BK4228","LU1668664300.SGD","BLUE","BK4556","BK4578","BK4588","BK4139"],"gpt_icon":0},{"id":"2538049348","title":"Gene Therapy Death Worsens Picture for an Already Troubled Field -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2538049348","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538049348?lang=en_us&edition=fundamental","pubTime":"2025-05-28 00:11","pubTimestamp":1748362260,"startTime":"0","endTime":"0","summary":"The death of a patient in a trial of an experimental gene therapy casts new shadows over a technology once seen as the future of the drug industry.Rocket Pharmaceuticals, a New Jersey-based biotech, said early Tuesday that a patient participating in a small trial of a gene therapy died over the weekend. The therapy is meant to treat a rare genetic condition called Danon Disease, which weakens the heart muscle and generally kills male patients in early adulthood. Rocket shares fell 58.6% on Tuesday.The gene therapy, called RP-A501, was being tested in a Phase 2 trial -- the last step before Rocket planned to submit the treatment for Food and Drug Administration approval. Analysts had been reasonably confident that the trial would be successful: In February, Jefferies analysts Andrew Tsai wrote that he put 65% to 75% odds on a positive readout.Or take Pfizer, which in 2019 unveiled plans to invest hundreds of millions of dollars in a \"state-of-the-art gene therapy manufacturing f","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0070302665.USD","BK4532","BK4588","LU0208291251.USD","BK4556","BK4578","BLUE","IE0002141913.USD","BK4139","LU0320765489.SGD","IE00BFTCPJ56.SGD","IE0009355771.USD","BK4007","NVS","IE00B2B36J28.USD","SRPT","BK4585","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","RCKT","LU0211331839.USD","IE00BJT1NW94.SGD"],"gpt_icon":1},{"id":"2538660334","title":"Bluebird Bio Urges Stockholders to Tender Shares as Carlyle and SK Capital Acquisition Deadline Approaches","url":"https://stock-news.laohu8.com/highlight/detail?id=2538660334","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538660334?lang=en_us&edition=fundamental","pubTime":"2025-05-27 20:30","pubTimestamp":1748349023,"startTime":"0","endTime":"0","summary":"Bluebird Bio Inc. has announced an update to its merger and acquisition transaction with Carlyle and SK Capital. The company has amended its agreement, providing stockholders with the option to receive either the original offer of $3.00 per share in cash plus a contingent value right of $6.84 per share in cash, contingent on achieving a net sales milestone, or a revised offer of $5.00 per share in cash. The transaction has received all necessary regulatory approvals and is expected to be finalized shortly after the tender offer deadline, which is set for May 29, 2025. Ayrmid Ltd. has confirmed it will not submit a competing proposal, solidifying the transaction with Carlyle and SK Capital as the sole option for Bluebird stockholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpret","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nNDL2pX4sg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLUE","BK4139","BK4578","BK4556"],"gpt_icon":0},{"id":"2538843395","title":"Sui Ecosystem Token Surges, SEND Sees 22% 24-hour Price Increase","url":"https://stock-news.laohu8.com/highlight/detail?id=2538843395","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538843395?lang=en_us&edition=fundamental","pubTime":"2025-05-27 11:28","pubTimestamp":1748316480,"startTime":"0","endTime":"0","summary":"BlockBeats News, May 27, according to HTX market data, the Sui ecosystem tokens have seen a revival, including:SEND's market cap is now $39.26 million, with a 24-hour increase of 22%;HIPPO's market cap is now $30.58 million, with a 24-hour increase of 10.1%;BLUE's market cap is now $38.80 million, with a 24-hour increase of 8.8%.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/295621","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["BK4139","BK4578","BK4556","BLUE","HIPO"],"gpt_icon":0},{"id":"2537715197","title":"Gilead Sciences Inc. Chief Commercial Officer Johanna Mercier Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2537715197","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537715197?lang=en_us&edition=fundamental","pubTime":"2025-05-24 03:17","pubTimestamp":1748027827,"startTime":"0","endTime":"0","summary":"Johanna Mercier, Chief Commercial Officer of Gilead Sciences Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 23, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nNDL7f4HdK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Gilead Sciences Inc. Chief Commercial Officer Johanna Mercier Reports Disposal of Common Shares","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3B42.SGD","LU1430594728.SGD","LU1066053197.SGD","IE00BKVL7J92.USD","IE00B7SZLL34.SGD","LU1585245621.USD","LU0109394709.USD","BK4583","BK4550","LU1571399168.USD","LU2087621335.USD","GILD","IE00BZ1G4Q59.USD","IE00B3T34201.USD","IE00BSNM7G36.USD","BK4588","LU1778281490.HKD","LU0234570918.USD","LU0058720904.USD","BK4532","BK4568","LU0823416689.USD","LU0889565916.HKD","LU2089984988.USD","LU2468319806.SGD","BK4139","BK4566","LU1674673691.USD","BK4585","IE0002270589.USD","LU1674673428.USD","LU1839511570.USD","LU0289739699.SGD","LU0320765992.SGD","IE00B19Z3581.USD","LU1066051498.USD","BK4578"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":38,"code":"91000000","status":"200"}]}}